JFA
CRSP icon

JNBA Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

JNBA Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110 Hold
2
– – ﹤0.01% 823
2026
Q1 		$96 Hold
2
– – ﹤0.01% 813
2025
Q4 		$105 Hold
2
– – ﹤0.01% 789
2025
Q3 		$130 Hold
2
– – ﹤0.01% 647
2025
Q2 		$98 Hold
2
– – ﹤0.01% 647
2025
Q1 		$69 Hold
2
– – ﹤0.01% 644
2024
Q4 		$79 Hold
2
– – ﹤0.01% 644
2024
Q3 		$94 Hold
2
– – ﹤0.01% 645
2024
Q2 		$109 Buy
+2
New +$116 ﹤0.01% 632

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

JNBA Financial Advisors's CRSP Position: Q2 2026 in Review

JNBA Financial Advisors held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 2 shares worth $110. The position accounts for ﹤0.01% of the portfolio, ranked #823.

JNBA Financial Advisors first reported a position in CRSP in Q2 2024 and has held it in 9 quarters since. The position peaked at $130 in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • JNBA Financial Advisors held 2 shares of CRISPR Therapeutics worth $110 as of Q2 2026.
  • JNBA Financial Advisors left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of JNBA Financial Advisors's portfolio in Q2 2026, its #823 holding.
  • JNBA Financial Advisors first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • JNBA Financial Advisors's CRISPR Therapeutics position peaked at $130 in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on JNBA Financial Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.